Australia Antigen in Singapore Chinese Patients With Hepatocellular Carcinoma

Simons, Margaret; Yu, May-Ing; Chew, B. K.; Tan, Aijun; Yap, E. H.; Seah, C. S.; Fung, W.P; Shanmugaratnam, K

doi:10.1016/s0140-6736(71)91660-6

Cited by 50 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of this higher frequency of Au Ag in patients with hepa toma and chronic fiver diseases, some investigators are trying to establish an étiologie relationship between the two agents [54], Vogel et al [54], who reported that 18 of 45 (40%) Ugandan patients with hepatoma had positive tests for Au Ag, found that it was not present in pa tients with other neoplasia. This low incidence of Au Ag, in cancer patients was also reported in cases from Singapore and the US [35,45]. In this study, we found that Au Ag was detectable in the sera of only 5 of 453 (1.1%) pa tients with advanced cancer.…”

Section: Discussionsupporting

confidence: 77%

“…Although Au Ag was detectable in the sera of patients with primary hepa tocellular carcinoma whose origins were from Uganda, Kenya, Senegal, Greece, and Britain, it was not detectable in patients with hepatoma from East Africa, Hong Kong, Singapore, or the United States [35,45,46], It is in teresting to note that in those hepatoma patients where the Au Ag was de tectable, a-1-fetoprotein was also found whenever the appropriate test was performed. Because of this higher frequency of Au Ag in patients with hepa toma and chronic fiver diseases, some investigators are trying to establish an étiologie relationship between the two agents [54], Vogel et al [54], who reported that 18 of 45 (40%) Ugandan patients with hepatoma had positive tests for Au Ag, found that it was not present in pa tients with other neoplasia.…”

Section: Discussionmentioning

confidence: 99%

“…The frequency of Au Ag is significantly higher in multiple-transfused lymphocytic leukemia patients than in non-leukemia patients who required repeated transfusion [51]. However, Au Ag has not been found in non-US patients (from Canada, Denmark, and Finland) with leukemia or Hodgkin's disease, even though they had received multiple blood transfusions [48], Furthermore, Au Ag has been detected in patients with hepatocellular carcinoma from certain geographical areas of the world [5,21,24,41,43,54], but remains persistently absent from the sera of patients from other coun tries, especially those from the US [35,45,46]. This study was designed to test for Au Ag in the sera of patients with nonresectable and advanced malignant tumors not originating from the reticulo endothelial tissues.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Incidence and Significance of Australia Antigen in Cancer Patients

Al‐Sarraf¹,

Kithier²,

Sardesai³

et al. 1973

Oncology

View full text Add to dashboard Cite

Australia antigen (Au Ag) has been found in a higher frequency in patients with acute hepatitis, leukemia or Hodgkin’s disease as compared to normal subjects, in this study, 759 sera from 453 patients with advanced cancer were tested for Au Ag by the double radical immunodiffusion of Ouchterlony and by counter-electrophoresis. In addition, 40 patients with different non-neoplastic disease, 45 with malignancy of reticuloendothelial (RE) tissues, and 15 with viral hepatitis were tested for the presence of Au Ag. The Au Ag was found in 5 (1.1%) of the cancer patients, and in 3 (60%) of 5 patients with serum hepatitis. No Au Ag was found in any other sera tested. None of the 12 patients with hepatoma were found to have Au AG, while α-1-fetoprotein was found in the sera in 8 of the cases.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Incidence and Significance of Australia Antigen in Cancer Patients

Al‐Sarraf¹,

Kithier²,

Sardesai³

et al. 1973

Oncology

View full text Add to dashboard Cite

show abstract

“…The prevalence of hepatitis B virus (HBV) markers varies considerably in differ ent parts of the world, a low prevalence, approximately 0.1% of HBsAg occurring in Western Europe, Scandinavia and North America [11], while carrier rates of up to and in excess of 10% have been reported for Africa and South East Asia [4,9].…”

Section: Introductionmentioning

confidence: 99%

Viral Hepatitis Markers in Thai Blood Donors

Seidel¹,

Chandanayingyong²

1984

Vox Sanguinis

View full text Add to dashboard Cite

1,410 voluntary blood donors from Bangkok were investigated by radioimmunoassay for HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe and anti-HAV. An HBsAg carrier state was observed in 10.7% of whom 42.1% were HBeAg positive and 40.2% had anti-HBe. Antibody prevalences (except anti-HBe) rose with increasing age. The occurrence of hepatitis markers did not vary significantly between donors living along the canals and those living in the Greater Bangkok area.

show abstract

“…[8] in 45 Americans and S imons el al. [14] in 114 Chinese patients. More recently, Smith and F rancis [16] found that the prevalence of HBAg in 50 cases of liver cell carcinoma from Nigeria was lower than in the blood donor population from the same country, but that of the antibody was slightly higher.…”

Section: Discussionmentioning

confidence: 99%

α-Fetoprotein and Australia Antigen in Primary Liver Cancer

Dammacco¹,

Miglietta²,

Antonaci³

et al. 1973

Digestion

View full text Add to dashboard Cite

Sera from patients with neoplastic and non-neoplastic diseases, as well as from full-term newborns and pregnant women were examined for the presence of α-fetoprotein (α-FP) by counterimmunoelectrophoresis. α-FP was detected in primary hepatoma (59%) and gonadal teratoblastoma. Positive results were also obtained in a case of colonic carcinoma metastatic to the liver and in 100% of cord blood sera. Since counter-immunoelectrophoresis is approximately intermediate between double diffusion and radioimmunoassay in terms of degree of sensitivity, it was proposed that this technique should be employed routinely for clinical purposes. The frequency of the hepatitis-associated antigen (HBAg) was determined in the sera of hepatoma patients and of two control groups consisting of healthy blood donors and patients with malignant tumors other than hepatoma. HBAg was present in 1 (4.5%) of the 22 hepatoma sera. By comparison, it was detected in 1 (4%) of the 25 sera belonging to the neoplastic series and in 5 (1.9%) of 950 blood donors. It is suggested that primary hepatoma is not directly related to chronic hepatitis and/or presence of HBAg. When, however, peculiar relationships occur between host and the hepatitis virus, viral hepatitis may progress to liver-cell carcinoma through the intermediate stage of postnecrotic cirrhosis.

show abstract

Australia Antigen in Singapore Chinese Patients With Hepatocellular Carcinoma

Cited by 50 publications

References 9 publications

The Incidence and Significance of Australia Antigen in Cancer Patients

The Incidence and Significance of Australia Antigen in Cancer Patients

Viral Hepatitis Markers in Thai Blood Donors

α-Fetoprotein and Australia Antigen in Primary Liver Cancer

Contact Info

Product

Resources

About